Following Report of $1.3 Billion in Potential Losses From Medicaid Drug Rebate Program–McCaskill Calls for Action, Answers
"We are deeply concerned about these potentially longstanding weaknesses in the agency's oversight of the accuracy of drug classifications for the purposes of the Medicaid drug rebate program," wrote the bipartisan group of Senators to the
A recent report from the internal watchdog that oversees the Medicaid program found that 885 drugs were potentially misclassified in the Medicaid drug rebate program, and the top 10 potentially misclassified drugs potentially cost Medicaid
McCaskill has made tackling rising healthcare and prescription drug costs a top priority in the
McCaskill recently introduced legislation to end taxpayer subsidies pharmaceutical companies receive for the billions of dollars they spend on prescription drug advertising each year, which currently is fully tax-deductible. Additionally, McCaskill's bipartisan legislation to increase competition for generic drugs and help lower prescription costs was signed into law by
Full text of letter HERE (https://www.mccaskill.senate.gov/download/letter-to-cms-on-medicaid-drug-rebates).
Black Women Need Better Access to Reproductive Healthcare
Rep. Blaine’s Bulletin: Happy Easter
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News